

Manuscript Details

Manuscript number	IJBIOMAC_2018_6721_R1
Title	Chitosan coated human serum albumin nanoparticles: a promising strategy for nose-to-brain drug delivery.
Article type	Research Paper

Abstract

The aim of the present study was the development of human serum albumin nanoparticles (HSA NPs) as nose-to-brain carrier. To strengthen, the efficacy of nanoparticles as drug delivery system, the influence of chitosan (CS) coating on the performance of HSA NPs was investigated for nasal application. HSA NPs were prepared by desolvation technique. CS coating was obtained adding the CS solution to HSA NPs. The mean particle size was 241 ± 18 nm and 261 ± 8 nm and the ζ -potential was -47 ± 3 mV and $+45 \pm 1$ mV for HSA NPs and CS-HSA NPs, respectively. The optimized formulations showed excellent stability upon storage both as suspension and as freeze-dried product after 3 months. The mucoadhesion properties were assessed by turbidimetric and indirect method. NPs were loaded with sulforhodamine B sodium salt as model drug and the effect of CS coating was investigated performing release studies, permeation and uptake experiments using Caco-2 and hCMEC/D3 cells as model of the nasal epithelium and blood-brain barrier, respectively. Furthermore, ex vivo diffusion experiments have been carried out using rabbit nasal mucosa. Finally, the ability of the formulations to reversibly open tight and gap junctions was explored by western blotting and RT-PCR analyzing in both Caco-2 and hCMEC/D3 cells.

Keywords Albumin nanoparticles; Chitosan; nose to brain.

Manuscript category Carbohydrates, Natural Polyacids and Lignins

Corresponding Author Maria Camilla Bergonzi

Corresponding Author's Institution Department of Chemistry

Order of Authors Vieri Piazzini, Elisa Landucci, Mario D'Ambrosio, laura tiozzo fasiolo, Lorenzo Cinci, Gaia Colombo, Domenico Edoardo Pellegrini-Giampietro, anna rita billia, Cristina Luceri, Maria Camilla Bergonzi

Suggested reviewers Carmelo Puglia, Silvia Fossati, Ylenia Zambito

Submission Files Included in this PDF

File Name [File Type]

Cover letter R1 IJBM.docx [Cover Letter]

Replies to Editor and Reviewers.docx [Response to Reviewers]

AbstractR1.docx [Abstract]

IJBIOMAC_2018_6721R1.docx [Manuscript File]

Captions to figures.docx [Figure]

FIG 1 REVISED.tiff [Figure]

FIG 2 REVISED_2.tiff [Figure]

Fig. 6.tif [Figure]

FIG 7_REVISED.pptx [Figure]

FIG 10.tiff [Figure]

Figure 13.tif [Figure]

Figure 14.tif [Figure]

Submission Files Not Included in this PDF

File Name [File Type]

FIG 3_REVISIED.xls [Figure]

FIG 4_REVISIED.xls [Figure]

FIG 5_REVISIED.xls [Figure]

FIG 8_REVISIED.xls [Figure]

FIG 9_REVISIED.xls [Figure]

FIG 11_REVISIED.xls [Figure]

Fig.12_REVISIED.xlsx [Figure]

FIG 15_REVISIED.xls [Figure]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.



UNIVERSITÀ
DEGLI STUDI
FIRENZE

DIPARTIMENTO
DI CHIMICA
"UGO SCHIFF"

Dear Editor,

Please find attached the revised manuscript entitled "Chitosan coated human serum albumin nanoparticles: a promising strategy for nose-to-brain drug delivery" (IJBIMAC_2018_6721), that my colleagues and me would submit for consideration for the publication in International Journal of Biological Macromolecules.

The manuscript was entirely revised according to reviewers' and Editor's comments. The revisions have been highlighted in yellow in the manuscript. In addition, the manuscript was corrected by a native English speaker and the corrections have been written in red.

All authors have read and approved this version of the article, and no part of this paper has been published nor is it submitted for publication elsewhere.

We thank you in advance for consideration.

Best regards.

Prof. Maria Camilla Bergonzi, Ph.D.

Maria Camilla Bergonzi

Comments from the editors and reviewers:

-Editor

As IJBIOMAC is a journal focusing on biological macromolecules, authors are required to provide basic characteristics of biomacromolecules used in the study, rather than simply stating they were purchased from suppliers or simply citing authors' previous paper, without detailed information about characteristics. The basic characteristics include molecular weight, viscosity, substitution degree (if applicable), structure and composition (if applicable), deacetylation degree (for chitosan), etc.

The characteristics of human serum albumin, mucin and chitosan were reported.

-Reviewer 1

-

The research paper describes the Chitosan coated human serum albumin nanoparticles: a promising strategy for nose-to-brain drug delivery. This work is methodically carried out and well written. In my opinion, the paper needs further improvements before being considered for publication according to the following comments/suggestions.

1. There are several papers on chitosan coated nanoparticles for the nose to brain delivery. Please state novelty of this work.

The novelty of our study was highlighted in the introduction.

2. Chemical crosslinker (glutaraldehyde) used is toxic in nature. Is there any other crosslinker can be used for safety?

The reviewer is right; there are several compounds able to perform the cross-linking reaction, besides glutaraldehyde: the enzyme transglutaminase, the carbodiimide and the natural compound genipin. In a previous paper (ChemMedChem 2016, 11, 1 – 11) the authors also tested a lesser-known thermal cross-linking method to prepare albumin nanoparticles.

However, glutaraldehyde as cross-linker is widely used to stabilize the albumin nanoparticles by crosslinking of amino acids residues in the protein (Int. J. Biol. Macromol. 115 (2018) 83–89). Glutaraldehyde-crosslinked albumin behaves as a network to hold the drug molecules inside the nanoparticles (Colloids Surf. B: Biointerfaces 123 (2014) 286–292).

Glutaraldehyde forms a very stable aldehyde bond which prevents burst release of drug from the nanoparticle after the administration (K.A. Gawde et al. Colloids and Surfaces B: Biointerfaces 167 (2018) 8–19). Moreover, the Glutaraldehyde generates intra- and inter-molecular covalent bridges that increased the stability of NPs.

In the procedure reported by the authors, glutaraldehyde was used in the lowest possible concentration, useful to harden the coacervate and corresponding to 100% of the amount required for the cross-linking of the 60 amino groups of HSA. Among the different tested concentrations (from 50% to 200% of the calculated amount required for the cross-linking of the amino groups of HSA), the best results concerning particle size, homogeneity, yield and reproducibility were obtained with the 100% concentration

Besides, the *in vitro* studies with two different cell lines, Caco-2 and *hCMEC/D3*, have supported the biocompatibility of the formulation.

3. Authors should add rpm in below mention sentences

“Afterwards, 5 mL of CS solution was added to an equal volume of HSA NPs suspension under magnetic stirring at a speed of 250 at room temperature.

rpm was added.

4. Procedure for TEM studies needs to be included.

The procedure was added

5. Table 2 legends should come at top of the table.

The legends of the Tables have been moved at the top of the Tables.

6. Authors should include release mechanism of a model drug from nanocarriers such as fickian or non fickian or case transport mechanism after applying korsenmayer peppas model.

The n values were reported.

7. Authors evaluated "The surface morphology on NPs by using transmission electron microscopy"; but the authors can do dimensional analysis as well with TEM and can correlate with PCS. If there is a discrepancy between mean particle size determined by PCS and the particles shown in the TEM, authors can discuss these findings as shown in various research papers. Tzeyung et al., *Pharmaceutics*. 2019 Jan 10;11(1).

As reported in the “Results and discussion” (pag 14) TEM analysis of HAS NPs confirms the presence of spherical HSA NPs with uniform size distribution in the range of 230-250 nm, according to the PCS measurements. In the case of CS-HAS NPs, the same correlation between TEM and PCS data was found and made explicit in the text (pag 15). The small difference in the data obtained with the two techniques is discussed according to literature.

8. Authors can remove figure 2 as there was no any comparison between drug-loaded nanoparticle and drug suspension for in vitro release study. Authors can include the value in the text.

I did not understand what the reviewer means. The figure 2 (TEM image of CS-HAS NPs) is now modified according to reviewer’s 2 comments and it was reported in the manuscript to highlight the presence of CS coating compared to uncoated particles and to confirm the DLS data. As reported in tables 1 and 2, the presence of the fluorescent model drug SalB does not affect the sizes of the carrier. In the *in vitro* release study (Fig 5) release profiles of SulfB solution and SulfB-loaded NPs were showed. The probe is soluble in water.

9. There are many places typo, grammatical and syntax error need to be corrected.

The manuscript was entirely revised.

-Reviewer 2

- 1. In TEM image, please add highly populated nanoparticles image with proper magnification.

TEM images (Figure 1 and 2) were modified.

2. All figures are not appearing in the manuscript in pdf file.

As reported in the Guide for authors, in the “Formats” section, if the electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) the images can be supplied in the native document format. Some figures of our manuscript are loaded in the .xls or .ppt format. These figures are not present in the pdf file, but as separated files.

Abstract

The aim of the present study was the development of human serum albumin nanoparticles (HSA NPs) as nose-to-brain carrier. To strengthen, the efficacy of nanoparticles as drug delivery system, the influence of chitosan (CS) coating on the performance of HSA NPs was investigated for nasal application. HSA NPs were prepared by desolvation technique. CS coating was obtained adding the CS solution to HSA NPs. The mean particle size was 241 ± 18 nm and 261 ± 8 nm and the ζ -potential was -47 ± 3 mV and $+45\pm 1$ mV for HSA NPs and CS-HSA NPs, respectively. The optimized formulations showed excellent stability upon storage both as suspension and as freeze-dried product after 3 months. The mucoadhesion properties were assessed by turbidimetric and indirect method. NPs were loaded with sulforhodamine B sodium salt as model drug and the effect of CS coating was investigated performing release studies, permeation and uptake experiments using Caco-2 and hCMEC/D3 cells as model of the nasal epithelium and blood-brain barrier, respectively. Furthermore, *ex vivo* diffusion experiments have been carried out using rabbit nasal mucosa. Finally, the ability of the formulations to reversibly open tight and gap junctions was explored by western blotting and RT-PCR analyzing in both Caco-2 and hCMEC/D3 cells.

1
2
3
4 **Chitosan coated human serum albumin nanoparticles:**
5 **a promising strategy for nose-to-brain drug delivery.**
6
7
8

9 Vieri Piazzini^{1#}, Elisa Landucci^{2#}, Mario D'Ambrosio³, Laura Tiozzo Fasiolo^{4,5}, Lorenzo
10 Cinci³, Gaia Colombo⁵, Domenico E. Pellegrini-Giampietro², Anna Rita Bilia¹, Cristina
11 Luceri³, Maria Camilla Bergonzi^{1*}
12
13

14 ¹Department of Chemistry, via U. Schiff 6, 50519 Sesto Fiorentino, Florence, Italy

15 ²Department of Health Sciences, Section of Clinical Pharmacology and Oncology, Viale
16 Pieraccini 6, 50139 Florence, Italy.

17 ³Department of NEUROFARBA, Department of Neurosciences, Psychology, Drug Research
18 and Child Health, Section of pharmacology and Toxicology, Viale Pieraccini 6, 50139
19 Florence, Italy.

20 ⁴Department of Department of Food and Drug, via delle Scienze 27/A, 43124 Parma, Italy.

21 ⁵Department of Department of Life Sciences and Biotechnology, Via Fossato di Mortara 17/19,
22 44121 Ferrara, Italy
23
24
25
26

27 # These authors contributed equally to this work.
28
29

30 **Corresponding author**

31 Prof. Maria Camilla Bergonzi, University of Florence, Department of Chemistry, via U. Schiff
32 6, 50019 Sesto Fiorentino, (FI), Italy.
33
34

35 E-mail: mc.bergonzi@unifi.it phone: +39 055-457 3678.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

61
62
63
64 **Abstract**
65

66 The aim of the present study was the development of human serum albumin nanoparticles (HSA
67 NPs) as nose-to-brain carrier. To strengthen, the efficacy of nanoparticles as drug delivery
68 system, the influence of chitosan (CS) coating on the performance of HSA NPs was investigated
69 for nasal application. HSA NPs were prepared by desolvation technique. CS coating was
70 obtained adding the CS solution to HSA NPs. The mean particle sizes was 241 ± 18 nm and
71 261 ± 8 nm and the ζ -potential was -47 ± 3 mV and $+45\pm 1$ mV for HSA NPs and CS-HSA NPs,
72 respectively. The optimized formulations showed excellent stability upon storage both as
73 suspension and as freeze-dried product after 3 months. The mucoadhesion properties were
74 assessed by turbidimetric and indirect method. NPs were loaded with sulforhodamine B sodium
75 salt as model drug and the effect of CS coating was investigated performing release studies,
76 permeation and uptake experiments using Caco-2 and hCMEC/D3 cells as model of the nasal
77 epithelium and blood-brain barrier, respectively. Furthermore, *ex vivo* diffusion experiments
78 have been carried out using rabbit nasal mucosa. Finally, the ability of the formulations to
79 reversibly open tight and gap junctions was explored by western blotting and RT-PCR
80 analyzing in both Caco-2 and hCMEC/D3 cells.
81
82
83
84
85
86
87
88
89
90

91 **Keywords**
92

93 Albumin nanoparticles; Chitosan; Caco-2 cell; hCMEC/D3 cells; rabbit nasal mucosa; nose to
94 brain.
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120

1. Introduction

Most of the drugs, in particular hydrophilic molecules and high molecular weight compounds, are not favourably absorbed by the brain due to the presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier, that cause a selective permeability to circulating molecules [1,2]. In the last years, the nose-to-brain (NTB) delivery is emerging strategy to overcome these barriers and delivery the drug directly into the brain. An increasing number of products are being developed and are reaching the market, such as vaccines, painkillers, anti-migraine and anti-cancer drugs and hormones [3,4].

The intranasal route allows the administration of drugs both locally and systemically avoiding the typical gastrointestinal degradation of oral administration and the effect of hepatic metabolism. The rich vascularization of the nasal mucosa provides a series of unique attributes that can increase the safety, the patient compliance, the rate of absorption of the drug and, consequently, the speed of onset of the therapeutic effect. Furthermore, the nasal mucosa, is easily accessible compared to other membranes and it is a favourable entry route for both small and large molecules. The nasal bioavailability of small molecules is good and the drugs that are not absorbed orally can be conveyed to the nasal systemic circulation. Nasally administered drugs can rapidly reach the brain through different pathways: the first is the olfactory nerves, that represent the main direct pathway for the NTB drug delivery; then the trigeminal nerves, which have nerve endings in the respiratory epithelia; finally, the respiratory epithelium through which the drugs reach the circulation and subsequent cross the BBB [1,5,6].

However, the NTB delivery is characterized by several limitations such as the small volume of the nasal cavity, the mucociliary clearance, the enzymatic degradation, the low drug retention time, the potential nasomucosal toxicity, the technique of drug administration and deposition and the necessity of a suitable delivery device [4,7,8].

To overcome these drawbacks, pharmaceutical nanotechnologies appear as an ideal formulation strategy for the NTB delivery [1,4,6-9]. In this context, the aim of the present study was the development of human serum albumin nanoparticles (HSA NPs) as NTB carrier and the investigation of the effect of chitosan (CS) coating on their performance, in particular with respect to the surface and mucoadhesive properties, stability, drug release modulation, biocompatibility and permeability.

HSA is an endogenous protein, non-toxic, non-immunogenic, biodegradable and biocompatible. Moreover, it displays good mucoadhesive properties, suitable for prolonging the residence time in the nasal cavity. HSA enhances cellular uptake by its active targeting

181 properties and it can show conformational modifications to increase its stability [11,12].
182
183
184 Furthermore, as reported in literature, albumin is an ideal **substance** for the development of
185
186 nanocarriers with the aim of **increasing** bioavailability, stability and pharmacological effects of
187
188 synthetics and plant-derived molecules [13-18].

189 HSA NPs were **employed** for the NTB delivery of the anti-Alzheimer drugs tacrine and *R*-
190
191 flurbiprofen [19,20].

192 CS, a polysaccharide derived from deacetylation of chitin, was also employed for its ability to
193
194 reversibly open tight junctions, with the potential to increase the drug permeation across the
195
196 nasal mucosa and the extracellular transport along the olfactory and trigeminal nerves. Besides,
197
198 positively charged CS can increase the drug residence time of the loaded drug in the nasal
199
200 cavity, due to the electrostatic interactions with the negatively charged epithelial cells or the
201
202 ability to absorb water from the mucus layer, forming a gel-like layer that increases the contact
203
204 with the site of absorption [4,21,22,23]. CS NPs and other CS derived formulations were
205
206 investigated for nose to brain delivery [22]

207 Various HSA and CS NPs have been utilized to deliver anticancer agents at the tumor. Proteins
208
209 and polysaccharides-based nanocarriers have great potential as drug delivery based on their
210
211 biocompatibility, biodegradability, ease of functionalization, improved biodistribution and
212
213 reduced toxicity effects [21,24,25]. The main application of CS coated formulations is for the
214
215 oral administration. CS-coated PLGA and PCL NPs were considered for nasal delivery [5,26].
216
217 CS-coated HSA (CS-HSA NPs) nanoparticles functionalized by MUC1 aptamer have
218
219 previously reported to load paclitaxel and investigate the specific targeting potential in human
220
221 breast tumor cells, MCF7 and T47D [21]. However, the present study is the first application of
222
223 CS-HSA NPs for NTB delivery. The surface charges modification of NPs from negative, with
224
225 HAS, to positive in the presence of CS have also considered due to its important effect on the
226
227 interaction with cell membranes and on cellular uptake [21].

228 Developed HAS NPs and CS-HAS NPs were physically and chemically characterized by Light
229
230 Scattering techniques (DLS and ELS), Transmission Electron Microscopy and High
231
232 Performance Liquid Chromatography. The freeze-drying process was evaluated **as technique to**
233
234 **increase NPs stability**. The mucoadhesion properties were assessed through the turbidimetric
235
236 method and the evaluation of the change in the ζ -potential value. HSA NPs and CS-HSA NPs
237
238 were loaded with sulforhodamine B sodium salt (**SulfB**) as a model of a hydrophilic drug
239
240 (**SulfB-HAS NPs** and **SulfB-CS-HAS NPs**) and the effect of CS coating was investigated **with**
respect to the release behaviour, the cellular permeation and the uptake using Caco-2 and

241
242
243
244 hCMEC/D3 cells as model of the nasal epithelium and BBB, respectively [15,23,27-30].
245
246 Furthermore, *ex vivo* diffusion experiments were performed using rabbit nasal mucosa in a
247 Franz-type permeation apparatus. The possible effects of the two formulations on tight and gap
248 junctions expression were assessed by exposing Caco-2 and hCMEC/D3 cells to HSA NPs and
249 CS-HSA NPs and by measuring the expression of Tight Junction Protein 1 (TJP1, also known
250 as zona occludens protein-1), at the protein and RNA levels.
251
252
253

254 255 **2. Material and methods**

256 257 *2.1 Material*

258
259 Sigma-Aldrich (Milan, Italy) provided all chemicals, analytical grade and HPLC grade
260 solvents. Human serum albumin (Sigma-Aldrich, Milan, Italy; cat n. SPR6182, mol wt 66.4
261 kDa). Chitosan low molecular weight (Sigma-Aldrich, Milan, Italy; cat n. 448869, mol wt.
262 50,000-190,000 Da, viscosity 20-300 cP, 1 wt. % in 1% acetic acid, 25 °C, Brookfield). Mucin
263 from porcine stomach (Sigma-Aldrich, Milan, Italy; cat n. M1778, Type III, bound sialic acid
264 0.5-1.5 %). Water was purified by a Milli-Q_{plus} system (Millipore Milford, CT, USA).
265 Phosphotungstic acid (PTA) was from Electron Microscopy Sciences (Hatfield, PA, USA).
266 Dialysis kit was from Spectrum Laboratories, Inc. (Breda, The Netherlands).
267
268
269
270
271
272
273

274 275 *2.2 Methods*

276 277 *2.2.1 Preparation of human serum albumin nanoparticles*

278 HSA NPs were prepared by the desolvation-coacervation technique [31,32], with some
279 modifications. HSA (30 mg) was dissolved in 3 mL of 10 mM NaCl solution under magnetic
280 stirring. The pH value was adjusted between 8 and 9 with NaOH 0.1 N. Then, ethanol was
281 added at a constant rate using a syringe until turbidity appeared in the solution. The obtained
282 coacervates were hardened by the addition of 5% glutaraldehyde solution, corresponding to
283 100% of the amount required for the cross-linking of the 60 amino groups of HSA. After 2 h
284 under magnetic stirring at room temperature, ethanol was vacuum evaporated, and the pellet
285 was redispersed in distilled water.
286
287
288
289

290 In addition, fluorescent NPs (SulfB-HAS NPs) were prepared, adding sulforhodamine B
291 sodium salt ($\lambda_{ex}=565$ nm, $\lambda_{em}=586$ nm in water, SulfB) to the HSA solution (final concentration
292 0.1 mg/mL). The resulted mixture was incubated for 2 h under magnetic stirring at 500 rpm,
293 before the addition of ethanol [11].
294
295
296
297
298
299
300

2.2.2 Preparation of chitosan-coated nanoparticles

CS-HSA NPs were obtained exploiting the ionic interactions between negatively charged HSA NPs and positively charged CS [21]. Firstly, CS was dissolved in 1% v/v glacial acetic acid at the concentration of 1 mg/mL. After 24 h under stirring at room temperature, the solution was filtered through a 0.45 μm membrane and then, the pH was adjusted to 4.5 with NaOH diluted solution (0.1 N). Afterwards, 5 mL of CS solution was added to an equal volume of HSA NPs suspension under magnetic stirring at a speed of 250 rpm at room temperature. The stirring was maintained for 15 min to allow the stabilization of the CS coating.

SulfB-CS-HSA NPs were prepared by adding CS solution to SulfB-HAS NPs suspension.

2.2.3 Physical characterization

Particle size, the polydispersity index (PDI) and ζ -potential have been measured a Zsizer Nanoseries ZS90 instrument (Malvern Instrument, Worcestershire, UK). The analyses were performed in triplicate.

2.2.4 TEM

The morphological characterization of NPs was analyzed by transmission electron microscopy (Jeol 1010, Tokyo, Japan). The samples were prepared as previously reported [29]. They were properly diluted with distilled water, then they were dropped on a 200 mesh carbon film-covered copper grid and negatively stained with a phosphotungstic acid aqueous solution (1% w/v). After drying, the grid containing the samples were observed with the TEM.

2.2.5 NPs yield determination

In order to evaluate the amount of HSA transformed into nanoparticles, 1.5 mL of HSA NPs and CS-HSA NPs were centrifuged at 21773 x g for 45 min. Then, the obtained supernatants were analyzed by HPLC [33].

The chromatograph was a HP 1200 liquid chromatograph coupled with a diode-array-detector (DAD) (Agilent Technologies, Santa Clara, CA, USA). The column was a Luna Omega Polar (150 mm \times 3 mm, 5 μm) (Agilent Technologies, Santa Clara, CA, USA). The mobile phases were: (A) formic acid/water pH 3.2 and (B) acetonitrile. The flow rate was 0.5 mL/min. The multi-step linear solvent gradient applied was: 0-2 min, 90% A, 10% B; 2-7 min, 90-60% A, 10-40% B; 7-17 min, 60-30% A, 40-70% B; 17-20 min, 30-10% A, 70-90% B; 20-22 min 10% A, 90% B; 22-27 min, 10-90% A, 90-10% B with post-time of 8 min. UV detection was carried

361
362
363
364 out at a wavelength of 280 nm [33]. The linearity was determined on five concentration levels
365
366 of HSA dissolved in distilled water (from 0.1 to 1 mg/mL) with three injections for each level.
367
368 The coefficient of linear correlation is above than 0.999.
369

370 371 *2.2.6 Determination of Encapsulation Efficiency (EE%)*

372 EE% was determined by the dialysis bag method. The membrane (cut-off 3.5 kD) was filled
373
374 with 2 mL of the samples, and kept for 1 h in 1 L of distilled water, to remove the free SulfB.
375
376 Then the samples were diluted with a CH₃CN/H₂O 70:30 mixture, sonicated and analyzed by
377
378 HPLC. SulfB analyses were performed using the same instrument, column and analytical
379
380 method reported for HSA analysis, but the chromatograms were acquired at 560 nm. The EE%
381
382 has been calculated as follows:
383

$$384 \text{ Encapsulation efficiency \%} = \frac{\text{SulfB encapsulated}}{\text{Total SulfB}} \times 100$$

388 389 *2.2.7 Nanoparticle freeze-drying*

390 An aliquot of HSA NPs and CS-HSA NPs was lyophilized as such, other three aliquots were
391
392 freeze-dried in the presence of D-Glucose anhydrous or D-Mannitol or D-Sucrose as
393
394 cryoprotective agents (2% w/v) [34]. After the freeze-drying process, each sample was
395
396 reconstituted with the original volume of distilled water, vortexed for few minutes to ensure the
397
398 complete redispersion of the powder [34] and analyzed for particle size, polydispersity and ζ-
399
400 potential.
401

402 403 *2.2.8 Stability studies*

404 Stability studies were conducted for three months. Particle size, PdI and ζ-potential were
405
406 evaluated at 4°C for HSA NPs and CS-HSA NPs suspensions, and at room temperature for
407
408 freeze-dried products.
409

410 411 *2.2.9 Mucoadhesion properties*

412 To evaluate and compare the mucoadhesion properties of both NPs in the presence of mucin,
413
414 the turbidimetric method [35] and the evaluation of the ζ-potential (indirect method) were
415
416 applied [36,37]. An equal volume of nanoparticles suspension and 1% w/v mucin aqueous
417
418 solution were mixed. Then, the resulted samples were vortexed for 1 min and incubated in a
419
420

421
422
423
424 water bath for 1 h at 37°C. The turbidity of the mixtures was evaluated spectrophotometrically
425 at $\lambda = 500$ nm. The absorbances of individual mucin and nanoparticle suspensions were also
426 recorded. The interaction between mucin and HSA NPs or CS-HSA NPs was calculated using
427 the following equation:
428
429

$$430 \quad \Delta A = A - A_{\text{theor}}$$

431
432 where ΔA is the absorbance difference, A is the effective absorbance of HSA NPs-mucin and
433 CS-HSA NPs-mucin mixtures and A_{theor} represents the sum between the individual absorbance
434 of mucin and nanoparticles suspensions. If $\Delta A = 0$, no interactions occur, whereas if $\Delta A \gg 0$
435 there is a strong interaction between nanoparticles and mucin.
436
437

438 The ζ -potential was measured as previously reported.
439
440
441

442 2.2.10 *In vitro release studies*

443
444 Dialysis bag method was applied for the *in vitro* release studies in physiological pH conditions
445 (PBS pH 7.4). For these studies regenerated cellulose membranes (cut-off of 3.5 kD) were
446 chosen for retaining the nanoparticles and allowing for the diffusion of the entrapped compound
447 into the dissolution medium. SulfB-HAS NPs, SulfB-CS-HSA NPs or SulfB aqueous solution
448 (2 mL) were added into dialysis membranes and placed in 200 mL of release medium. Thus,
449 the systems were incubated at 37°C with stirring at 150 rpm. At predetermined time intervals
450 (0, 0.5, 1, 2, 4, 5, 8 and 24 h) 1 mL of the medium was withdrawn and replaced with the same
451 volume of fresh release medium maintained at 37°C to preserve sink conditions. SulfB released
452 at each time interval was quantified using HPLC. All experiments were performed in triplicate.
453 Different mathematical models were used to understand the kinetic and the mechanism of drug
454 release from HSA NPs and CS-HSA NPs. The best-fitted model was defined based on the
455 highest R^2 value of the release curve.
456
457
458
459
460
461
462
463

464 2.2.11 *Experiments with Caco-2 cells*

465 *Caco-2 cell line*

466
467 Caco-2 cells (human colorectal adenocarcinoma) were from American Tissue Type Culture
468 Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium with
469 20% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin in 5% CO_2 at 37 °C
470 (Thermo Fisher Scientific, Rodano, Milan, Italy).
471
472
473
474
475
476
477
478
479
480

Cell Culture Experiments

The cell viability was assessed using MTS assay, as previously described [38]. The cells were exposed to HSA NPs and CS-HSA NPs at different dilutions (from 1:10 to 1:40) for 2 and 24 h. The relative cell viability was expressed as a percentage of the untreated control group.

Transport Studies

Caco-2 cells were seeded into 12-well PET transwell plates (1.13 cm² growth surface area and pore size 0.4 μm, Greiner Bio-One, Milan, Italy) at a density of 2 × 10⁴ cells/cm². A confluent monolayer was obtained after 21 days.

SulfB-HSA NPs and SulfB-CS-HSA NPs diluted 10 times were incubated for 4 h in the apical compartment. Lucifer Yellow (LY) was used to check the integrity of the cellular layer during the permeability test [39]. At 0 (before sample addition), 60, 120, 180 and 240 min, samples were taken from the basal compartment of each transwell plate and fresh HBSS was added. The SulfB concentration was determined by HPLC.

Mucin staining

To highlight the presence of mucin production on the Caco-2 cells monolayer, cells were seeded and cultured for 21 days in specific chamber-slide for cytological analysis (X-well tissue culture chambers, Sarstedt, Verona, Italy). After 21 days of culture, cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature. Slides were rinsed in 3% acetic acid solution and incubated for 2 hours in 1% alcian-blue solution, then, were rinsed in H₂O, oxidized for 10 minutes in 1% periodic acid solution and incubated for 10 minutes in Schiff reactive. Slides were finally rinsed in H₂O and washed three times in 0.5% sodium bisulfite solution, dehydrated and mounted. Nuclei were counterstained with hematoxylin for 30 seconds.

Cell uptake Studies

Caco-2 cells were pre-incubated with sodium azide (1 μM), chlorpromazine (15 μM), and indomethacin (25 μM) for 30 min followed by the addition of SulfB-HSA NPs or SulfB-CS-HSA NPs 1:10 for 1 h, or maintained at 4°C during the NPs exposure. At the end of the experiments, the SulfB quantity remaining in the cellular lysate was quantified by HPLC analyses.

541
542
543
544 *2.2.12 Experiments with hCMEC/D3 cells*

545
546 *hCMEC/D3 cell line*

547 The brain microvascular endothelial cell line hCMEC/D3 (Millipore) derives from human
548 temporal lobe microvessels isolated from epilepsy control obtained by medical surgery. Cell
549 were seeded and grown as previously reported [29]. Cell were maintained at 37°C in an
550 incubator in atmosphere of humidified air and 5% CO₂ and the EndoGRO medium
551 supplemented with 1 ng/mL FGF-2 was changed thrice a week. Cells were passaged at least
552 twice before use. Accumax TM Cell Counting Solution in DPBS was used to split the confluent
553 cells.
554
555
556
557
558

559
560 *MTT assay*

561 The cell viability after HSA NPs and CS-HSA NPs exposure in hCMEC/D3 cell was assessed
562 by MTT assay [40,41]. After pre-coated of the 24-well plate with Collagen Type I, Rat Tail,
563 the cells were seeded and maintained until they were approximately 70-80% confluent. HSA
564 NPs and CS-HSA NPs were incubated at different concentrations (dilution 1:10, 1:100 and
565 1:500) of the formulation for 2 and 24 h in the complete medium (EBM-2). A part of the
566 medium of each treatment was taken and preserved for LDH assay, and cells were incubated
567 with MTT at the concentration of 1 mg/mL. Finally, DMSO was used to dissolve MTT
568 formation and absorbance was recorded at 550 and 690 nm. EBM-2 was used as positive control
569 and Triton X-100 as negative control and the cell viability was expressed as a percentage
570 compared to the cells incubated only with EBM-2.
571
572
573
574
575
576
577
578

579
580 *LDH assay*

581 The extent of cell death after HSA NPs and CS-HSA NPs exposure was quantitatively evaluated
582 by measuring the amount of LDH release from injured cells, as previously described [29]. The
583 LDH level corresponding to complete cell death was obtained in the presence of triton X-100
584 (positive control). All the values were expressed as a percentage compared to TX release, EBM-
585 2 was used as the negative control.
586
587
588
589

590
591 *hCMEC/D3 cell culture for transwell permeability studies*

592 High-density pore (2 x10⁶ pores/cm²) transparent PET membrane filter inserts (0.4 μm, 23,1
593 mm diameter, Falcon, Corning BV, Netherlands) in 6-well plates were used for all transcytosis
594 assays as previous described [29]. After 1h of coating with rat tail collagen type I the membrane
595
596
597
598
599
600

601
602
603
604 filter inserts, the cells were seeded onto the apical side of the inserts at a density of 6×10^4
605 cells/cm². hCMEC/D3 monolayers were used to perform the permeability assay for SulfB-HSA
606 NPs and SulfB-CS-HSA NPs. The integrity of the monolayer cells was controlled using
607 fluorescein sodium salt (NaF) at a concentration of 10 µg/mL [15], and by observation of
608 cultures under phase-contrast microscopy [28] using an inverted microscope (Olympus IX-50;
609 Solent Scientific, Segensworth, UK) with (20X). For permeability studies, SulfB-HSA NPs and
610 SulfB-CS-HSA NPs, diluted 10 times were tested and incubated for 1, 2 and 3 h in the apical
611 donor compartment. NaF and SulfB were quantified in both in compartments by HPLC-FLD
612 or HPLC-DAD analyses.
613
614
615
616
617
618
619

620 *Cell uptake Studies*

621 Sodium azide (1 µM), chlorpromazine (15 µM) and indomethacin (25 µM) were used to
622 understand the uptake mechanism of the developed nanoparticles. The drugs were preincubated
623 for 30 min before the addition of SulfB-HSA NPs or SulfB-CS-HSA NPs for 2h at the dilution
624 of 1:10. The quantity of SulfB was measured on cellular lysate by HPLC analyses at the end of
625 the test.
626
627
628
629
630

631 *Western blotting*

632 hCMEC/D3 and Caco-2 cells were seeded into 6-well plates at a density of 1.2×10^6 cells/cm²
633 and after exposure to HSA NPs and CS-HSA NPs at the dilution of 1:10 for 2 h, the cells (1
634 well/sample) were washed with cold 0.01 M PBS, pH 7.4 and were transferred and dissolved
635 in a tube containing 1% SDS. The Pierce (Rockford, IL, USA) BCA (bicinchoninic acid)
636 Protein Assay Total was used to quantify the protein levels. Lysates (20 µg/lane of protein)
637 were resolved by electrophoresis on a 4-20% SDS-polyacrylamide gel (Bio-Rad Laboratories,
638 Hercules, CA, USA) and transferred onto nitrocellulose membranes. Blots were blocked for 1
639 h at room temperature in 20 mM Tris-buffered saline, pH 7.6-0.1% Tween 20 (TBS-T)
640 containing 5% non-fat dry milk, and then incubated overnight at 4°C with rat monoclonal
641 antibodies against ZO1, mouse monoclonal antibodies against claudin-5 (all from Santa Cruz
642 Biotechnology, CA, U.S.A) diluted 1:300 in TBS-T containing 5% non-fat dry milk or
643 polyclonal-rabbit antibody against Ve-Chaderin (from Cell Signaling Technology, Beverly,
644 MA, USA) diluted 1:1000 in TBS-T containing 5% bovine serum albumin. The loading control
645 anti-β-actin antibody was monoclonal from Sigma (St Louis, MO, USA). Immunodetection was
646 performed with secondary antibodies (1:2000 anti-rat, anti-mouse or anti-rabbit IgG from
647
648
649
650
651
652
653
654
655
656
657
658
659
660

661
662
663
664 donkey, Amersham Biosciences, UK) conjugated to horseradish peroxidase in TBS-T
665 containing 5% non-fat dry milk. Membranes were washed with TBS-T and then reactive bands
666 were detected using chemiluminescence (ECLplus; Euroclone, Padova, Italy). Quantitative
667 analysis was performed using the QuantityOne analysis software (Bio-Rad, Hercules, CA,
668 USA).
669
670
671

672 673 674 *RT-PCR*

675 hCMEC/D3 and Caco-2 cells were seeded into 12-well plates at a density of 1.0×10^5 cells/cm².
676 After exposure to HSA NPs and CS-HSA NPs at the dilution of 1:10 for 2 h, the cells were
677 washed with Dulbecco-s phosphate-buffered saline. The Nucleo Spin[®] RNA kit (Macherey-
678 Nagel, Bethlehem, USA) were used to extract the total RNA from cell lysates.

682 For first-strand cDNA synthesis, 1 µg of total RNA from each sample was reverse-transcribed
683 by using the RevertAid RT Kit (Thermo Scientific, Waltham, MA USA). Primers were
684 designed on the basis of the GenBank sequences for homo sapiens Tight Junction Protein 1,
685 TJP1 (NM_003257.4): forward primer 5'-GGGAGCACATGGTGAAGGTAA-3', reverse
686 primer 5'- ATCACAGTGTGGTAAGCGCA-3'. GAPDH was co-amplified as reference gene:
687 forward primer 5'-CCCTCAAGGGCATCCTGGGCT-3', reverse primer 5'-
688 GCAGGGACTCCCCAGCAGTGA-3'. PCR products were carried out using 1 µl of cDNA in a 25 µl
689 total volume containing 1x PCR buffer, 0.5 mM dNTPs, 8 ng/µl of primer, 0.1 ng/µl of GAPDH
690 primers and 1.25 units of Taq polymerase (Dream Taq, Carlo Erba, Milan, Italy). The PCR
691 conditions were: 95°C for 5 min and 30 cycles at 95°C for 30 sec, 60°C for 30 sec and 72°C for
692 55 sec. PCR products were separated on a agarose gel (1.8%) and visualized by Safeview
693 staining (Euroclone, Milan, Italy). Gel images were captured by an UVIdocHD2 acquired
694 system (Eppendorf, Milan, Italy) and the intensity of the bands were analysed with the
695 Quantity-One software (Bio-Rad, Segrate, Milan, Italy).
696
697
698
699
700
701
702
703
704

705 706 *2.2.13 Ex vivo transport experiments across rabbit nasal mucosa*

707 *Ex vivo* transport experiments were performed using rabbit nasal mucosa in a Franz-type
708 diffusion apparatus (0.58 cm² permeation area, VETROTECNICA S.r.l., Padova, Italy) [42-
709 44]. On the day of the experiment, rabbit heads were collected from a local slaughterhouse
710 (Pola S.r.l, Finale Emilia, Italy) and transported to the laboratory in a refrigerated box. The
711 extraction procedure, completed within 2 h from the animal's death, and the protocol to treat
712 the nasal mucosa are described elsewhere [45].
713
714
715
716
717
718
719
720

721
722
723
724 Before introducing the NPs in the donor compartment, the receptor compartment was filled
725 with PBS and the assembled system was allowed to equilibrate at 37°C for half an hour.
726

727
728 In particular, SulfB-HSA NPs, SulfB-CS-HSA NPs and SulfB aqueous solution were tested by
729 maintaining the concentration of SulfB constant in all the samples (0.1 mg/mL).
730

731 The experiments were carried out over a 4 h and 24 h period of time. This experiment duration
732 was consistent with the data in literature about tissue viability and drug transport experiments
733 across animal excised nasal mucosa, employing nano-drug delivery systems [46-51].
734

735 At predetermined time points, a volume of receptor solution (0.5 mL) was withdrawn, and the
736 receptor compartment refilled with an equivalent volume of fresh PBS. At the end of the
737 experiment, the mass balance (sum of the amounts of SulB recovered from receptor, donor and
738 membrane) was calculated. For this aim, the residual formulation on the membrane was
739 quantitatively recovered by rinsing the donor compartment with PBS. In addition, SulfB
740 retained at the membrane nasal mucosa was extracted with distilled water using an IKA T25
741 digital Ultra-Turrax (IKA-Works, Staufen im Breisgau, Germany) for 10 min and then an
742 ultrasound bath for 30 min. All the samples were analyzed by HPLC.
743

744 The flux of SulfB across the mucosa in steady-state conditions was calculated according to the
745 solution of Fick Equation [43].
746
747

748 749 750 751 752 753 *2.2.14 Statistical analysis*

754 The experiments were performed in triplicate. The results were expressed as a mean ± S.D.
755 (standard deviation). Statistical analyses cells viability, permeability studies and cellular uptake
756 were performed using one-way ANOVA followed by the post hoc Tukey's w-test for multiple
757 comparisons. GRAPH-PAD PRISM v. 5 for Windows (GraphPad Software, San Diego, CA,
758 USA) was applied to all statistical calculations. A P value < 0.05 was considered significant.
759
760
761
762

763 764 **3. Results and Discussion**

765 766 767 *3.1 HSA NPs characteristics*

768 HSA NPs were obtained by the desolvation-coacervation technique [31,32]. The hydrodynamic
769 diameter of the nanoparticles is one of the most crucial parameters that affect the nose-to-brain
770 absorption. Indeed, only small particles can be transported to the brain via the olfactory or the
771 trigeminal nerves [1]. For this reason, the pH of the HSA solution was adjusted between 8 and
772
773
774
775
776
777

9 considering that the particle size decreased with increasing pH [32]. NaCl was selected because other salts interfere with the desolvation and cross-linking process [32,52].

Ethanol was used as desolvating agent due to its dielectric constant, dipole moment and solubility parameter that make it an ideal solvent to enter into the hydrophobic region of HSA, disrupt the hydrophilic layer of the protein in water, and to induce the denaturation of HSA and consequently the formation of NPs [53]. Besides, ethanol is less toxic compared to other organic solvents proposed as desolvating agents, i.e., acetone, methanol and acetonitrile [54,55].

Glutaraldehyde aqueous solution was chosen as cross-linker agent [32]. Among the different tested concentrations (from 50% to 200% of the calculated amount required for the cross-linking of the amino groups of HSA), the best results concerning particle size, homogeneity, yield and reproducibility were obtained with the 100% concentration (Table 1).

The morphological appearance of NPs confirmed the presence of spherical HSA NPs with uniform size distribution in the range of 230-250 nm, according to the DLS measurements (Figure 1).

The surface charge of the developed HSA NPs was negative due to the presence of the terminal carboxyl groups of the protein. The high ζ -potential value indicates the presence of strong repulsive forces which can prevent the aggregation of the NPs, increasing the stability of the formulation (Table 1). Besides, the negative surface charge is crucial for further surface modification step.

Table 1. Physical and chemical characterization of empty and SulfB-HSA NPs. Data displayed as mean \pm SD; n=3.

Sample	Size (nm)	PdI	ζ -potential (mV)	EE%	Yield %
HSA NPs	241 \pm 19	0.06 \pm 0.04	-47 \pm 3	-	93 \pm 1
SulfB-HSA NPs	244 \pm 12	0.11 \pm 0.02	-44 \pm 5	65 \pm 2	95 \pm 2

The nanoparticle yield, determined by HPLC analyses as previously reported in the literature [33], was very high, indicating that almost all HSA was converted into NPs. Thus, the obtained results demonstrated the success of the preparative process.

SulfB, a hydrophilic fluorescent dye, was incorporated into HSA NPs (SulfB-HSA NPs) as hydrophilic drug model to perform release studies and *in vitro* experiments with Caco-2 and hCMEC/D3 cells and to investigate the permeation across the rabbit nasal mucosa. SulfB was

841
842
843
844 selected because it does not have a pH-dependent absorption or fluorescence over the range of
845 3 to 10 and it is highly soluble in the media employed in the *in vitro/ex vivo* assays. **The**
846 **incorporation of SulfB did not negatively affect the size and homogeneity of HSA NPs, as**
847 **reported in Table 1.**
848
849
850
851

852 3.2 CS-HSA NPs characteristics

853
854 CS-HSA NPs were obtained by the electrostatic interaction between negatively charged HSA
855 NPs and positively charged CS [21]. Low molecular weight CS was used according to
856 Bonaccorso [5]. The increase in particle size and the inversion of ζ -potential value clearly
857 indicated the interaction between HSA NPs and CS [37] (Table 2). The high ζ -potential is
858 related to a stable formulation in which the electrostatic repulsions prevent the aggregation. The
859 positive surface charge of CS-HSA NPs is also fundamental for further **interaction** with
860 negatively charged cell membranes and to improve the mucoadhesive properties.
861

862 Different CS concentrations were tested (from 1 mg/mL to 3 mg/mL). As CS concentration
863 increased, particle enlargement (greater than 300 nm) and broadening of the size distribution
864 (PDI > 0.3) were observed, while the ζ -potential remained unchanged. Eventually, CS was
865 employed at the concentration of 0.1 mg/mL (Table 2).
866

867 TEM micrographs provided information on morphology and dimensions of the NPs and showed
868 the presence of CS on the surface of HSA NPs as a grey shell (Figure 2) [37,56,57].
869 **Dimensional analysis with TEM (220-230 nm) correlated with DLS values. The little difference**
870 **between the results obtained with the two analytical techniques could be due to different sample**
871 **preparation: the dehydration of CS NPs in the case of TEM leads to measurement of the particle**
872 **which is smaller than hydrodynamic particles, as previously reported [28].** The other
873 physicochemical properties of HSA NPs such as PDI, EE% and the nanoparticle yield were not
874 affected by the presence of CS.
875
876
877
878
879
880
881
882
883
884
885

886 **Table 2.** Physical and chemical characteristics of empty and SulfB-CS-HSA NPs. Data
887 displayed as mean \pm SD; n=3.
888

891 Sample	892 Size (nm)	893 PDI	894 ζ -Potential (mV)	895 EE%	896 Yield %
897 CS-HSA NPs	898 261 \pm 8	899 0.10 \pm 0.07	900 +45 \pm 1	-	94 \pm 1
SulfB-CS-HSA NPs	267 \pm 6	0.12 \pm 0.02	+44 \pm 1	63 \pm 1	95 \pm 3

3.3 Nanoparticles freeze-drying

The freeze-drying process improves the long-term stability of nanoparticles and limits the microbial proliferation caused by the presence of the aqueous medium. In this perspective, HSA NPs and CS-HSA NPs were freeze-dried without cryoprotectants and in the presence of sugars or sugar alcohols such as glucose, sucrose and mannitol. Fast freezing rate with liquid nitrogen was preferred because it avoids the formation of large ice crystals, which could damage the NPs and reduces their aggregation [59,60]. In the absence of cryoprotectant, a significant increase in size and a loss of size homogeneity were observed for both formulations (Table 3). This result confirmed the advantage of cryoprotectants in preventing the aggregation of albumin NPs during the freeze-drying process [34].

Table 3. Physical parameters of HSA NPs and CS-HSA NPs after the freeze-drying process without and with different cryoprotectants. Data displayed as mean \pm SD; n=3.

Freeze-dried product	Size (nm)	PdI	ζ -potential (mV)
HSA NPs	> 500 nm	> 0.5	-
HSA NPs + Glucose	269 \pm 3	0.05 \pm 0.01	-45 \pm 2
HSA NPs + Mannitol	262 \pm 5	0.06 \pm 0.01	-44 \pm 1
HSA NPs + Sucrose	261 \pm 1	0.06 \pm 0.01	-45 \pm 1
CS-HSA NPs	> 500 nm	> 0.5	-
CS-HSA NPs + Glucose	276 \pm 5	0.12 \pm 0.02	+31 \pm 1
CS-HSA NPs + Mannitol	285 \pm 2	0.11 \pm 0.01	+17 \pm 3
CS-HSA NPs + Sucrose	269 \pm 3	0.06 \pm 0.01	+35 \pm 1

All the cryoprotectants were tested at the concentration of 2% w/v. The best performance in terms of technological aspects was obtained with sucrose (Table 3). A slight size increase was found, nevertheless the NPs maintained physical characteristics suitable for the intranasal application.

Non-reducing compounds such as mannitol and sucrose are generally preferred to avoid potential Maillard reaction of the cryoprotectant with the protein [61]. Sucrose resulted better than mannitol in particular for CS-HSA NPs, so it was selected for storage stability studies. A possible reason for this result could be the tendency of mannitol to crystallize during the freeze-drying process [61].

3.4 Storage stability studies

Physical stability of HSA NPs and CS-HSA NPs as suspension and as freeze-dried product was monitored during three months. Both HSA NPs and CS-HSA NPs suspensions resulted stable at 4°C. The final values of particle size and PDI for HSA NPs were 238 ± 5 and 0.10 ± 0.01 , respectively, while for CS-HSA NPs they resulted 265 ± 2 and 0.11 ± 0.01 , respectively. No significant changes were also found for ζ -potential after 3 months of storage: -47 ± 1 for HSA NPs and $+43 \pm 2$ for CS-HSA NPs.

A similar study was performed on freeze-dried NPs. Both products maintained almost the same initial physical characteristics: size 260 ± 3 nm, PDI 0.07 ± 0.01 and ζ -potential of -40 ± 1 mV, in the case of HSA NPs; and size 265 ± 1 nm, PDI 0.06 ± 0.01 and ζ -potential of $+37 \pm 2$ mV, in the case of CS-HSA NPs. These data demonstrate that the developed NPs can be stored as suspension in the fridge and potentially even at room temperature as freeze-dried products for long periods.

Stability of SulfB loaded NPs was also considered. They were physically and chemically stable at 37°C and in the light for three days. These results were also important for the subsequent *in vitro* and *ex vivo* experiments.

3.5 Mucoadhesion properties

Turbidity analyses and the evaluation of the ζ -potential were synergistically applied to investigate and compare the mucoadhesion properties of CS-HSA NPs and uncoated NPs.

As clearly reported in Figure 3, a significant increase in absorbance difference (ΔA) was found in the case of CS-HSA NPs indicating a strong interaction between positively charged amino groups present in CS and the negatively charged carboxyl and sulphate groups of the mucin [36, 62]. ζ -potential analyses confirmed the data obtained by the turbidimetric method. Positive charges of CS-HSA NPs were neutralized by the negative charges of mucin (Figure 4). On the other hand, uncoated NPs remain negatively charged once the interaction with mucin occurs at lower extension [36,63].

3.6 In vitro release experiments

In vitro release profiles of the dye from the aqueous solution, the SulfB-HSA NPs and the SulfB-CS-HSA NPs suspensions are reported in Figure 5. In the case of the solution, 100% of SulfB was released after 2 h, while in the case of both formulations the immediate release of the entrapped molecule, known as burst effect, was very low. This represents an important

1021
1022
1023
1024
1025 finding because it suggests that the drug leakage during *in vivo* delivery would be minimal. The
1026 release of SulfB from CS-HSA NPs started quite slower respect to HSA NPs, then, after about
1027 four hours, the release profiles of the formulations became similar as a consequence of CS
1028 hydration and swelling (Figure 5) [51,64].

1029
1030 As previously reported, the release kinetics of SulfB, employed as a model of a hydrophilic
1031 drug, were analysed by Hixson-Crowell, Higuchi, first- and zero-order mathematical models.
1032 The results revealed that the release of SulfB from both formulations was diffusion-controlled,
1033 as indicated by higher R-squared (R^2) values in the Higuchi model (0.839 for HSA NPs and
1034 0.884 for CS-HSA NPs).

1035
1036
1037
1038
1039 When the release data were analyzed using the Korsmeyer–Peppas model, the values of the
1040 diffusional exponent n were found to be 0.68 and 0.67 for HSA NPs and CS-HSA NPs,
1041 respectively, demonstrating that the SulfB release follows a non-Fickian diffusion mechanism.
1042
1043

1044 3.7 Caco-2 experiments

1045
1046 Caco-2 cell line was used as model of the nasal epithelium [23,30]. The cells used for the test
1047 are rich in mucin content, an important feature also to evaluate the effect of chitosan coating on
1048 the permeation.
1049

1050
1051 After Alcian-blue PAS reaction, Caco-2 cells appeared stained in magenta, highlighting the
1052 presence of neutral mucins (Figure 6). This kind of mucins usually reacts with PAS. The lack
1053 of blue staining highlighted the absence of acid mucins [65].
1054

1055
1056 A first set of experiments was performed to select the suitable dilution of NPs dispersions for
1057 further studies, i.e., permeation and uptake experiments. For this purpose, cell viability (MTS)
1058 assay was carried out. As reported in Figure 7 (panel a), when Caco-2 cells were exposed for 4
1059 h to different concentrations of SulfB-HSA NPs and SulfB-CS-HSA NPs (dilution from 1:40 to
1060 1:10) the cell viability was not reduced. Further experiments demonstrated that when the cells
1061 were incubated with the two types of SulfB-NPs for 24 h, diluted 10 times, the cell viability was
1062 not significantly affected compared to the control group (Figure 7, panel b).
1063

1064
1065 Since the developed formulations are designed for nasal administration, and the nasal
1066 epithelium represents the first barrier, these results demonstrate their biocompatibility,
1067 independently of the surface charge.
1068

1069
1070 The permeation studies across the Caco-2 monolayer revealed that the P_{app} values of SulfB-HSA
1071 NPs and SulfB-CS-HSA NPs were similar for the first 3 hours (Figure 8). This is probably
1072 related to the mucoadhesive characteristics that CS conveys to the NPs. A delayed drug release
1073 occurs in the presence of CS-coating [56,66,67]. However, after 4 h of incubation, the P_{app} value
1074
1075
1076
1077
1078

1081
1082
1083
1084 of SulfB-CS-HSA NPs was higher, **about twice** the P_{app} value of SulfB-HSA NPs (Figure 8).
1085
1086 Finally, the obtained P_{app} results are useful for *in vitro* prediction, as confirmed by the recovery
1087 values, which were above 80% in all experiments [27].
1088

1089 To elucidate the endocytic uptake mechanism and to differentiate SulfB-HSA NPs and SulfB-
1090 CS-HSA NPs, the uptake experiments were carried out in the presence of sodium azide as
1091 energy depletion agent, chlorpromazine, a clathrin-dependent endocytosis inhibitor and
1092 indomethacin, as caveolin-dependent endocytosis inhibitor. As evidenced in Figure 9, the
1093 cellular uptake of both NPs was significantly inhibited in the presence of sodium azide,
1094 chlorpromazine and indomethacin with **a more pronounced** effect of all the inhibitors in the
1095 case of uncoated NPs. These data indicated that both formulations, were internalized by energy-
1096 dependent mechanism and the clathrin-mediated endocytosis resulted the main pathway
1097 involved in the uptake, consistent with the results obtained in other works with similar
1098 formulations [68].
1099
1100
1101
1102
1103
1104

1105 1106 1107 3.8 hCMEC/D3 experiments

1108 The possible toxic effects of the NPS were evaluated by MTT and LDH assays in hCMEC/D3
1109 cell line (Figure 10). The same cells were used for permeability studies. When cells were
1110 exposed to HSA NPs and CS-HSA NPs (from dilution 1:500, 1:100 and 1:10) for 2 and 24 h,
1111 no significant changes were observed in MTT metabolism, or LDH release respected to cells
1112 incubated with only complete medium indicating that HSA NPs and CS-HSA NPs did not affect
1113 the metabolic activity of the cells nor the membrane **integrity**.
1114
1115
1116

1117 A lot of study use the hCMEC/D3 cell line as a model of the human BBB and in particular for
1118 to understand the drug transport mechanisms [15, 27]. As the cells retain the expression of most
1119 transporters and receptors expressed *in vivo*, the permeability studies were performed to predict
1120 the permeability of SulfB-HSA NPs and SulfB-CS-HSA NPs across the BBB, after a possible
1121 absorption via the respiratory epithelium and achievement of the circulation, as indirect
1122 pathway for the NTB delivery. NaF was used as negative control and its P_{app} was calculated to
1123 monitor the integrity of the cell layer, together with the phase-contrast microscopy [28].
1124
1125
1126

1127 The permeation studies across hCMEC/D3 monolayer revealed that the P_{app} **value** of SulfB-CS-
1128 HSA NPs was higher than with SulfB-HSA NPs at 1 and 2 hours (Figure 11), this effect perhaps
1129 is in part **due to** the mechanism of action of CS which induces a reversible transient change of
1130 the tight junctions. However, after 3 h of incubation, the P_{app} **values** of SulfB-CS-HSA NPs and
1131 SulfB-HSA NPs **were** similar.
1132
1133
1134
1135
1136
1137
1138
1139
1140

1141
1142
1143
1144 To understand the possible endocytic uptake mechanism of the two different formulations, **the**
1145 **sodium azide**, as energy depletion agent, **the** chlorpromazine, a clathrin-dependent endocytosis
1146 inhibitor and **the** indomethacin, as caveolin-dependent endocytosis inhibitor, **were used**. As
1147 evidenced in Figure 12, the cellular uptake of SulfB-HSA NPs and SulfB-CS-HSA NPs was
1148 significantly **reduced in the presence of all three inhibitors with a greater effect in the case of**
1149 **uncoated NPs**. These data indicate that both formulations were internalized in an energy-
1150 dependent manner and the clathrin-mediated endocytosis was the main pathway involved in
1151 this uptake.
1152
1153
1154
1155
1156
1157
1158

1159 *3.9 Effects of nanoparticles on tight and gap junctions expression*

1160 Chitosan induced a significant decrease of the expression of gap junctions in hCMEC/D3 cells,
1161 but not in tight junctions in Caco-2 (data not shown). Exposure of the two cell lines to CS-HSA
1162 NPs at the 1:10 dilution for 2 h caused a decrease in the levels of ZO-1 expression significantly
1163 for hCMEC/D3, but not for Caco-2. However, HSA NPs did not alter the level of the protein
1164 (Fig. 13). In the hCMEC/D3 cells CS-HSA NPs decreased also the levels of Caudin-5 and Ve-
1165 Cadherin that **are** the most abundant gap junctions in these cells [27] (Fig.13). The different
1166 effect observed with the NPs in the two cell lines **can depend** on the different mechanisms of
1167 action of chitosan: **its effect on the gap junctions in the case of hCMEC/D3 cells, while the**
1168 **mucoadhesion in the case of Caco-2**.
1169
1170
1171
1172
1173
1174

1175 Variations of tight junctions (TJP1) expression were assessed also at RNA level, by RT-PCR.
1176 As shown in Figure 14 (panel a), the exposure to CS-HSA NPs and, at a lesser extent, to HSA
1177 NPs for 2 hours, significantly reduced the expression of ZO1 in hCMEC/D3 cells while these
1178 formulations did not significantly alter its expression in Caco-2 cells, confirming **the findings**
1179 **obtained** at the protein level (Fig. 13). The qualitative PCR confirmed the data obtained and
1180 shown in real time PCR (Fig. 14, panel b).
1181
1182
1183

1184 Overall, these data indicate that CS-HSA NPs have advantages in opening the tight junctions
1185 between hCMEC/D3 cells, a model of blood-brain barrier, allowing for the transport of
1186 molecules across the barrier. The effect on Caco-2 cells, on the contrary, indicated that these
1187 formulations can be safely used for nasal administration because intact epithelial tight junctions
1188 are crucial for maintaining barrier function. Mucoadhesion is the main mechanism at this level.
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200

3.10 Ex vivo transport experiments across rabbit nasal mucosa

The *ex vivo* permeation of SulfB from SulfB-HSA NPs, SulfB-CS-HSA NPs and aqueous solution was studied by using rabbit nasal mucosa as biological barrier [42-44]. The maximum permeation of SulfB in 24 h was 83.7% for CS-HSA NPs, 68.9% for HSA NPs and 45.5% in the case of the aqueous solution of the dye (Figure 13). The higher permeation of SulfB, when loaded into CS-HSA NPs could be due to the permeation enhancing activity of CS, in particular to the interaction of positively charged amino groups of CS with negatively charged cell membranes and to the opening of the tight junctions, as evidenced in the experiments with Caco-2 and hCMEC/D3 cells. On the other hand, the possible reason for the lower permeation of the free-SulfB in comparison to SulfB loaded into HSA NPs and CS-HSA NPs could be due to the hydrophilic nature of drug [49].

Besides, the apparent permeability coefficient of SulfB loaded into CS-HSA NPs resulted $16.7 \pm 1.3 \times 10^{-6}$ cm/s, while the permeation rates of HSA NPs and free-SulfB resulted $13.8 \pm 1.1 \times 10^{-6}$ cm/s and $9.1 \pm 0.1 \times 10^{-6}$ cm/s, respectively. A greater permeability coefficient is expected to correlate with enhanced absorption [69]. The obtained data are suitable for an accurate prediction since the mass balance values were 98.9 ± 1.6 % for SulfB-HSA NPs and 99.6 ± 0.6 % for SulfB-CS-HSA NPs.

The CS coating on the surface of HSA NPs determined a slower amount of SulfB permeated in particular during the first 6 hours, in comparison to uncoated NPs (Figure 15). This result is due to the mucoadhesive properties of CS-HSA NPs, which could result in an extended time of action, in accordance with the results obtained by the *in vitro* release studies and Caco-2 experiments [51,56,64,66,67].

The mucoadhesive properties of SulfB-CS-HSA NPs compared to SulfB-HSA NPs were also evidenced by the experiment performed for 4 h. As hypothesized, concerning the amount of SulfB recovered into the rabbit nasal mucosa after 4 h, CS-HSA NPs exhibited higher SulfB accumulation (6.7%) compared to HSA NPs (1.7%). These results demonstrated the strong interaction between CS and the mucin.

4. Conclusion

In this study, the influence of CS-coating on HSA NPs for nasal delivery was investigated for the first time. Concerning physical and chemical parameters, the use of chitosan-coated nanoparticles is a promising approach for nose-to-brain drug delivery. The freeze-drying process was optimized, and both NPs showed excellent storage stability properties as

1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320

suspensions, at 4°C, and as freeze-dried products. The functionalization coating with CS was confirmed by the difference in the ζ -potential value and also by TEM analysis. Besides, the mucoadhesive properties of CS and its ability to modulate the release of the entrapped molecule were proved by the turbidimetric and the indirect method and performing *in vitro* release studies. Caco-2 and hCMEC/D3 cell experiments, selected as model of nasal epithelium and BBB, respectively, evidenced the safety of the NPs and the **ability** of CS to increase the drug permeation. Both formulations were internalized into the cells **with the energy-dependent mechanism**, and the clathrin-mediated endocytosis was found to be the main pathway involved in this process.

The possible effects of the two formulations on tight and gap junctions expression were assessed **in both cellular lines**. CS-HSA NPs have the advantage of opening the tight junctions between hCMEC/D3 cells, by decreasing the levels of ZO-1 expression, allowing for the transport of molecules across the barrier. The effect was not **evidenced in the** Caco-2 cells. The different effect observed with the **NPs** in the two cell lines may be dependent on the different mechanisms of action of CS, in the case of hCMEC/D3 cells dependent on the gap junctions while in the case of Caco-2 **on** the mucoadhesion.

Ex-vivo studies using rabbit nasal mucosa demonstrated a strong interaction between CS and the mucosa and the higher penetrating potential of CS-HSA NPs respect to uncoated NPs. Consequently, the present research proposed a novel and promising strategy based on HSA NPs surface modification for the NTB delivery of many bioactives.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

TEM analyses were performed thanks to the collaboration with Dr. Maria Cristina Salvatici, Electron Microscopy Centre (Ce.M.E.), ICCOM, CNR, Sesto Fiorentino, Florence, Italy.

REFERENCES

- [1] A. Mistry, S. Stolnik, L. Illum, Nanoparticles for direct nose-to-brain delivery of drugs, *Int. J. Pharm.* 379 (2009) 146-157, <https://doi:10.1016/j.ijpharm.2009.06.019>
- [2] Y. Chen, L. Liu, Modern methods for delivery of drugs across the blood-brain barrier, *Adv. Drug Deliv. Rev.* 64 (2012) 640-665, <https://doi:10.1016/j.addr.2011.11.010>
- [3] A. Pires, A. Fortuna, G. Alves, A. Falcao, Intranasal Drug Delivery: How, Why and What for? *J. Pharm. Pharm. Sci.* 12 (2009) 288-311. <https://doi:10.18433/J3nc79>
- [4] F. Sonvico, A. Clementino, F. Buttini, G. Colombo, S. Pescina, S.S. Guterres, A.R. Pohlmann, S. Nicoli, Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting, *Pharmaceutics* 10 (2018) 34, <https://doi.org/10.3390/pharmaceutics10010034>
- [5] A. Bonaccorso, T. Musumeci, M.F. Serapide, R. Pellitteri, I. F. Uchegbu, G. Puglisi, Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization, *Colloids Surf. B Biointerfaces* 154, (2017) 297-306, <https://doi:10.1016/j.colsurfb.2017.03.035>
- [6] Y.H. Feng, H.S. He, F.Q. Li, Y. Lu, J.P. Qi, W. Wu, An update on the role of nanovehicles in nose-to-brain drug delivery. *Drug Discov. Today* 23 (2018) 1079-1088, <https://doi:10.1016/j.drudis.2018.01.005>
- [7] M. Agrawal, S. Saraf, S. Saraf, S.G. Antimisiaris, M.B. Chougule, S.A. Shoyele, A. Alexander, Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs, *J. Control. Release* 281 (2018) 139-177, <https://doi:10.1016/j.jconrel.2018.05.011>
- [6] Y.H. Feng, H.S. He, F.Q. Li, Y. Lu, J.P. Qi, W. Wu, An update on the role of nanovehicles in nose-to-brain drug delivery, *Drug Discov. Today* 23(5), (2018). 1079-1088. <https://doi:10.1016/j.drudis.2018.01.005>
- [8] S. Md, S.K. Bhattmisra, F. Zeeshan, N. Shahzad, M.A. Mujtaba, V.S. Meka, J. Ali, Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders, *J. Drug Deliv. Sci. Tec.* 43 (2018) 295-310, <https://doi:10.1016/j.jddst.2017.09.022>
- [9] E. Samaridou, M.J. Alonso, Nose-to-brain peptide delivery - The potential of nanotechnology, *Bioorg. Med. Chem.* 26 (2018) 2888-2905, <https://doi:10.1016/j.bmc.2017.11.001>
- [10] A.O. Elzoghby, W.M. Samy, N.A. Elgindy, Albumin-based nanoparticles as potential controlled release drug delivery systems, *J. Control. Release* 157 (2012) 168-182, <https://doi:10.1016/j.jconrel.2011.07.031>
- [11] M.C. Bergonzi, C. Guccione, C. Grossi, V. Piazzini, A. Torracchi, I. Luccarini, F. Casamenti, A.R. Bilia, Albumin Nanoparticles for Brain Delivery: A Comparison of Chemical

1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440

versus Thermal Methods and in vivo Behavior, ChemMedChem 11 (2016) 1840-1849, <https://doi:10.1002/cmdc.201600080>

[12] Y.L. Tan, H.K. Ho, Navigating albumin-based nanoparticles through various drug delivery routes, Drug Discov. Today 23 (2018) 1108-1114, <https://doi:10.1016/j.drudis.2018.01.051>

[13] A. Jithan, K. Madhavi, M. Madhavi, K. Prabhakar, Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer, Int. J. Pharm. Investig. 1 (2011) 119-125. <https://doi:10.4103/2230-973X.82432>

[14] B. Wilson, Y. Lavanya, S.R.B. Priyadarshini, M. Ramasamy, J. Leno Jenita, Albumin nanoparticles for the delivery of gabapentin: Preparation, characterization and pharmacodynamic studies, Int. J. Pharm. 473 (2014) 73-79, <http://dx.doi.org/10.1016/j.ijpharm.2014.05.056>

[15] C. Guccione, M. Oufir, V. Piazzini, D. E. Eigenmann, E. A. Jahne, V. Zabela, MT. Faleschini, M.C. Bergonzi, M. Smiesko, M. Hamburger, A.R. Bilia, Andrographolide-loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell line, Eur. J. Pharm. Biopharm. 120 (2017) 146-146, <http://doi:10.1016/j.ejpb.2017.09.010>

[16] J. B. Ferrado, A.A. Perez, F.F. Visentini, G.A. Islan, G.R. Castro, L.G. Santiago, Formation and characterization of self-assembled bovine serum albumin nanoparticles as chrysin delivery systems, Colloids Surf. B Biointerfaces 173 (2018) 43-51, <http://doi:10.1016/j.colsurfb.2018.09.046>

[17] M.M. Elgohary, M.W. Helmy, S.M. Mortada, A.O. Elzoghby, Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer, Nanomedicine (Lond) 13 (2018) 2221-2224, <http://doi:10.2217/nnm-2018-0097>

[18] F. Kratz, Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles, J. Control. Release 132, (2008) 171-183, <https://doi.org/10.1016/j.jconrel.2008.05.010>

[19] B. Luppi, F. Bigucci, G. Corace, A. Delucca, T. Cerchiara, M. Sorrenti, V. Zecchi, Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine, Eur. J. Pharm. Sci. 44 (2011) 559-565, <http://doi:10.1016/j.ejps.2011.10.002>

[20] L.R. Wong, P.C. Ho, Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease, J. Pharm. Pharmacol. 70 (2018) 59-69, <http://doi:10.1111/jphp.12836>

[21] M. Esfandyari-Manesh, A. Mohammadi, F. Atyabi, S.M. Nabavi, S.M. Ebrahimi, E. Shahmoradi, Varnamkhasti BS, M.H. Ghahremani, R. Dinarvand, Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer, Int. J. Pharm. 515 (2016) 607-615, <http://doi:10.1016/j.ijpharm.2016.10.066>

[22] L. Casettari, L. Illum, Chitosan in nasal delivery systems for therapeutic drugs. J. Control. Release 190 (2014) 189-200, <http://doi:10.1016/j.jconrel.2014.05.003>

1441
1442
1443
1444
1445 [23] G. Rasso, E. Soddu, M. Cossu, A. Brundu, G. Cerri, N. Marchetti, L. Ferraro, R.F. Regan,
1446 P. Giunchedi, E. Gavini, A. Dalpiaz, Solid microparticles based on chitosan or methyl-beta-
1447 cyclodextrin: a first formulative approach to increase the nose-to-brain transport of
1448 deferoxamine mesylate, *J. Control. Release* 201 (2015) 68-77,
1449 <http://doi:10.1016/j.jconrel.2015.01.025>
1450

1451 [24] Y.R. Li, H.L. Song, S.J. Xiong, T. Tian, T.B. Liu, Y.Y. Sun, Chitosan-stablized bovine
1452 serum albumin nanoparticles having ability to control the release of NELL-1 protein, *Int. J.*
1453 *Biol. Macromol.* 109 (2018) 672-680, <http://doi:10.1016/j.ijbiomac.2017.12.104>
1454

1455 [25] M. Gaber, M.T. Mabrouk, M.S. Freag, S.K. Khiste, J.Y. Fang, K.A. Elkhodairy, A.O.
1456 Elzoghby, Protein-polysaccharide nanohybrids: Hybridization techniques and drug delivery
1457 applications. *Eur J Pharm Biopharm.* 133 (2018) 42-62, <http://doi:10.1016/j.ejpb.2018.10.001>
1458

1459 [26] Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles
1460 Through Intranasal Route in the Treatment of Cerebral Ischemia. Niyaz Ahmad , Rizwan
1461 Ahmad, Md Aftab Alam, Farhan Jalees Ahmad *Drug Res (Stuttg)* 2018; 68(10): 584-595
1462 DOI: 10.1055/a-0596-7288
1463

1464 [27] D.E. Eigenmann, G. Xue, K.S. Kim, A.V. Moses, M. Hamburger, M. Oufir, Comparative
1465 study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC,
1466 TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier
1467 model for drug permeability studies, *Fluids Barriers CNS* 10 (2013) 33,
1468 <http://doi:10.1186/2045-8118-10-33>
1469

1470 [28] G. Graverini, V. Piazzini, E. Landucci, D. Pantano, P. Nardiello, F. Casamenti, D. Pantano,
1471 D.E. Pellegrini-Giampietro, A.R. Bilia, M.C. Bergonzi, Solid lipid nanoparticles for delivery
1472 of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation, *Colloids Surf.*
1473 *B Biointerfaces* 161 (2018) 302-313, <http://doi:10.1016/j.colsurfb.2017.10.062>
1474
1475

1476 [29] V. Piazzini, E. Landucci, G. Graverini, D.E. Pellegrini-Giampietro, A.R. Bilia, M.C.
1477 Bergonzi, Stealth and cationic nanoliposomes as drug delivery systems to increase
1478 andrographolide BBB permeability, *Pharmaceutics* 2018, 10, 128,
1479 <http://doi:10.3390/pharmaceutics10030128>
1480

1481 [30] G. Rasso, E. Soddu, A.M. Posadino, G. Pintus, B. Sarmiento, P. Giunchedi, E. Gavini,
1482 Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's
1483 therapy. *Colloids Surf. B Biointerfaces* 152 (2017) 296-301.
1484 <http://doi:10.1016/j.colsurfb.2017.01.031>
1485

1486 [31] C. Weber, C. Coester, J. Kreuter, K. Langer, Desolvation process and surface
1487 characterisation of protein nanoparticles, *Int. J. Pharm.* 194 (2000) 91-102,
1488 [https://doi.org/10.1016/S0378-5173\(99\)00370-1](https://doi.org/10.1016/S0378-5173(99)00370-1)
1489

1490 [32] K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, D. Schubert, Optimization
1491 of the preparation process for human serum albumin (HSA) nanoparticles. *Int. J. Pharm.* 257,
1492 (2003) 169-180, [https://doi.org/10.1016/S0378-5173\(03\)00134-0](https://doi.org/10.1016/S0378-5173(03)00134-0)
1493
1494
1495
1496
1497
1498
1499
1500

1501
1502
1503
1504 [33] M. Merodio, A. Arnedo, M.J. Renedo, J.M. Irache, Ganciclovir-loaded albumin
1505 nanoparticles: characterization and *in vitro* release properties. Eur. J. Pharm. Sci. 12 (2001)
1506 251-259, [https://doi.org/10.1016/S0928-0987\(00\)00169-X](https://doi.org/10.1016/S0928-0987(00)00169-X)
1507

1508 [34] M.G. Anhorn, H.C. Mahler, K. Langer, Freeze drying of human serum albumin (HSA)
1509 nanoparticles with different excipients, Int. J. Pharm. 363 (2008) 162-169.
1510 <https://doi:10.1016/j.ijpharm.2008.07.004>
1511

1512 [35] M.C. Bonferoni, G. Sandri, F. Ferrari, S. Rossi, V. Larghi, Y. Zambito, C. Caramella,
1513 Comparison of different *in vitro* and *ex vivo* methods to evaluate mucoadhesion of glycol-
1514 palmitoyl chitosan micelles, J. Drug Deliv. Sci. Tec. 20 (2010) 419-424,
1515 [https://doi:10.1016/S1773-2247\(10\)50073-X](https://doi:10.1016/S1773-2247(10)50073-X)
1516
1517

1518 [36] A.C.C. Vieira, L.L. Chaves, S. Pinheiro, S. Pinto, M. Pinheiro, S.C. Lima, . . . Reis, S.
1519 (2018). Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of
1520 tuberculosis. Int. J. Pharm. 536 478-485, <https://doi:10.1016/j.ijpharm.2017.11.071>
1521

1522 [37] V. Piazzini, L. Cinci, M. D'Ambrosio, C. Luceri, A.R. Bilia, M.C. Bergonzi, SLNs and
1523 Chitosan-coated SLNs as promising tool for silybin delivery: formulation, characterization, and
1524 *in vitro* evaluation Curr. Drug Deliv. 16 (2019) 142-152,
1525 <https://doi:10.2174/1567201815666181008153602>
1526

1527 [38] E. Bigagli, L. Cinci, M. D'Ambrosio, C. Luceri, Pharmacological activities of an eye drop
1528 containing Matricaria chamomilla and Euphrasia officinalis extracts in UVB-induced oxidative
1529 stress and inflammation of human corneal cells. J. Photochem. Photobiol. B, 173 (2017) 618-
1530 625, <https://doi:10.1016/j.jphotobiol.2017.06.031>
1531
1532

1533 [39] G. Iacomino, O. Fierro, S. D'Auria, G. Picariello, P. Ferranti, C. Liguori, F. Addeo, G.
1534 Mamone, Structural Analysis and Caco-2 Cell Permeability of the Celiac-Toxic A-Gliadin
1535 Peptide 31-55, J. Agric. Food Chem. 61 (2013) 1088-1096, <https://doi:10.1021/jf3045523>
1536

1537 [40] P. Conti, A. Pinto, L. Tamborini, U. Madsen, B. Nielsen, H. Brauner-Osborne, C. De
1538 Micheli, Novel 3-Carboxy- and 3-Phosphonopyrazoline Amino Acids as Potent and Selective
1539 NMDA Receptor Antagonists: Design, Synthesis, and Pharmacological Characterization,
1540 ChemMedChem 5 (2010) 1465-1475, <https://doi:10.1002/cmdc.201000184>
1541

1542 [41] E. Landucci, R. Lattanzi, E. Gerace, T. Scartabelli, G. Balboni, L. Negri, D.E. Pellegrini-
1543 Giampietro, Prokineticins are neuroprotective in models of cerebral ischemia and ischemic
1544 tolerance *in vitro*, Neuropharmacology 108 (2016) 39-48.
1545 <https://doi:10.1016/j.neuropharm.2016.04.043>
1546

1547 [42] P. Russo, C. Sacchetti, I. Pasquali, R. Bettini, G. Massimo, P. Colombo, A. Rossi, Primary
1548 microparticles and agglomerates of morphine for nasal insufflation. J. Pharm. Sci 95 (2006)
1549 2553-2561, <https://doi:10.1002/jps.20604>
1550
1551

1552 [43] F. Bortolotti, A.G. Balducci, F. Sonvico, P. Russo, G. Colombo, *In vitro* permeation of
1553 desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of
1554 potassium sorbate, Eur. J. Pharm. Sci. 37 (2009) 36-42, <https://doi:10.1016/j.ejps.2008.12.015>
1555
1556

- 1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
- [44] A. Giuliani, A.G. Balducci, E. Zironi, G. Colombo, F. Bortolotti, L. Lorenzini, V. Galligioni, G. Pagliuca, A. Scagliarini, L. Calzà, F. Sonvico, In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates, *Drug Deliv.* 25 (2018) 376-387, <https://doi:10.1080/10717544.2018.1428242>
- [45] A.G. Balducci, L. Ferraro, F. Bortolotti, C. Nastruzzi, P. Colombo, F. Sonvico, P. Russo, G. Colombo, Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats, *Int. J. Pharm.* 440 (2013) 154-160, <https://doi:10.1016/j.ijpharm.2012.09.049>
- [46] E. Bechgaard, S. Gizurarson, L. Jørgensen, R. Larsen, The viability of isolated rabbit nasal mucosa in the Ussing chamber, and the permeability of insulin across the membrane. *Int. J. Pharm.* 87 (1992) 125-132, [https://doi:10.1016/0378-5173\(92\)90235-t](https://doi:10.1016/0378-5173(92)90235-t)
- [47] M.C. Schmidt, Simmen, D., Hilbe, M., Boderke, P., Ditzinger, G., Sandow, J., S. Lang, W. Rubas, H. P. Merkle Validation of Excised Bovine Nasal Mucosa as In Vitro Model to Study Drug Transport and Metabolic Pathways in Nasal Epithelium, *J. Pharm. Sci.* 89 (2000) 396-407, [https://doi:10.1002/\(sici\)1520-6017\(200003\)89:3<396::Aid-jps10>3.0.Co:2-f](https://doi:10.1002/(sici)1520-6017(200003)89:3<396::Aid-jps10>3.0.Co:2-f)
- [48] P.M. Ved, K. Kim, Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain, *Int. J. Pharm.* 411 (2011) 1-9, <https://doi:10.1016/j.ijpharm.2011.02.040>
- [49] N.K. Bari, M. Fazil, M.Q. Hassan, M.R. Haider, B. Gaba, J.K. Narang, S. Baboota, J. Ali, Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder, *Int. J. Biol. Macromol.* 81 (2015) 49-59, <https://doi:10.1016/j.ijbiomac.2015.07.041>
- [50] A. Javia, H. Thakkar, Intranasal delivery of tapentadol hydrochloride-loaded chitosan nanoparticles: formulation, characterisation and its in vivo evaluation, *J. Microencapsul.* 34 (2017) 644-658, <https://doi:10.1080/02652048.2017.1375038>
- [51] R. Raj, S. Wairkar, V. Sridhar, R. Gaud, Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity, *Int. J. Biol. Macromol.* 109 (2018) 27-35, <https://doi:10.1016/j.ijbiomac.2017.12.056>
- [52] C.C. Westcott, (1978). *pH measurements*. New York a.o.: Academic Press.
- [53] H. Mohammad-Beigi, S.A. Shojaosadati, D. Morshedi, N. Mirzazadeh, A. Arpanaei, The Effects of Organic Solvents on the Physicochemical Properties of Human Serum Albumin Nanoparticles, *Iranian J. Biotechnol.* 14 (2016) 45-50, <https://doi:10.15171/ijb.1168>
- [54] S.S. Likhodii, I. Serbanescu, M.A. Cortez, P. Murphy, O.C. Snead, W.M. Burnham, Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet, *Ann. Neurol.* 54 (2003) 219-226, <https://doi:10.1002/ana.10634>
- [55] E. Adriaens, M.M., Dhondt, J.P. Remon, Refinement of the Slug Mucosal Irritation test as an alternative screening test for eye irritation, *Toxicol. In Vitro*, 19 (2005) 79-89, <https://doi:10.1016/j.tiv.2004.06.004>

- 1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
- [56] P. Fonte, T. Nogueira, C. Gehm, D. Ferreira, B. Sarmiento, Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin, *Drug Deliv. Transl. Res.* 1 (2011) 299-308, <https://doi.org/10.1007/s13346-011-0023-5>
- [57] L. Bugnicourt, C. Ladaviere, A close collaboration of chitosan with lipid colloidal carriers for drug delivery applications, *J. Control. Release* 256 (2017) 121-140, <https://doi.org/10.1016/j.jconrel.2017.04.018>
- [58] A.S. Tzeyung, S. Md, S.K. Bhattamisra, T. Madheswaran, N.A. Alhakamy, H.M. Aldawsari, A.K. Radhakrishnan, Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery. *Pharmaceutics* 11 (2019) 26. <https://doi.org/10.3390/pharmaceutics11010026>
- [59] W. Abdelwahed, G. Degobert, S. Stainmesse, H. Fessi, Freeze-drying of nanoparticles: formulation, process and storage considerations, *Adv. Drug Deliv. Rev.* 58 (2006) 1688-1713, <https://doi.org/10.1016/j.addr.2006.09.017>
- [60] M.K. Lee, M.Y. Kim, S. Kim, J. Lee, Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate, *J. Pharm. Sci.* 98 (2009) 4808-4817. <https://doi.org/10.1002/jps.21786>
- [61] H.R. Costantino, M. J. Pikal, *Lyophilization of biopharmaceuticals*. (2004) Arlington, VA: AAPS Press, c2004. ISBN 0971176760
- [62] Y.C. Luo, Z. Teng, Y. Li, Q. Wang, Solid lipid nanoparticles for oral drug delivery: Chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake, *Carbohydr. Polym.* 122 (2015) 221-229, <https://doi.org/10.1016/j.carbpol.2014.12.084>
- [63] A. Grenha, B. Seijo, C. Remunan-Lopez, Microencapsulated chitosan nanoparticles for lung protein delivery, *Eur. J. Pharm. Sci.* 25 (2005) 427-437, <https://doi.org/10.1016/j.ejps.2005.04.009>
- [64] R. Singh, J.W. Lillard, Nanoparticle-based targeted drug delivery, *Exp. Mol. Pathol.* 86 (2009) 215-223, <https://doi.org/10.1016/j.yexmp.2008.12.004>
- [65] A. Ferraretto, M. Bottani, P. De Luca, L. Cornaghi, F. Arnaboldi, M. Maggioni, A Fiorilli, E. Donetti, Morphofunctional properties of a differentiated Caco2/HT-29 co-culture as an in vitro model of human intestinal epithelium, *Biosci. Rep.* (2018) 38 BSR20171497, <https://doi.org/10.1042/BSR20171497>
- [66] C. Prego, M. Garcia, D. Torres, M.J. Alonso, Transmucosal macromolecular drug delivery, *J. Control. Release* 101 (2005) 151-162, <https://doi.org/10.1016/j.jconrel.2004.07.030>
- [67] F.N.S. Fachel, B. Medeiros-Neves, M. Dal Pra, R.S. Schuh, K.S. Veras, Bassani, V. L., L. Scherer Koester, A.M. Henriques, E. Braganhol, H. F. Teixeira, Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery-In vitro studies, *Carbohydr. Polym.* 199 (2018) 572-582, <https://doi.org/10.1016/j.carbpol.2018.07.054>

1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740

[68] H.J. Byeon, Q. Thao le, S. Lee, S.Y. Min, E.S. Lee, B.S. Shin, Y.S. Youn, Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. *J. Control. Release* 225 (2016) 301-313, <https://doi:10.1016/j.jconrel.2016.01.046>

[69] G. Chen, D. Svirskis, W. Lu, M. Ying, Y. Huang, J. Wen, N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. *J. Control. Release* 277 (2018) 142-153. <https://doi:10.1016/j.jconrel.2018.03.013>

Captions to figures

Figure 1. TEM image of HSA NPs.

Figure 2. TEM image of CS-HSA NPs.

Figure 3. Turbidimetric method. Absorbance difference of mucin admixed with HSA NPs and CS-HSA NPs. Data displayed as mean \pm SD; n=3. ** $p < 0.01$ vs. HSA NPs (ANOVA + Tukey's test).

Figure 4. Indirect method. ζ -potential of HSA NPs and CS-HSA NPs after incubation with mucin. Data displayed as mean \pm SD; n=3.

Figure 5. *In vitro* release profiles of SulfB solution, SulfB-loaded HSA NPs and SulfB-loaded CS-HSA NPs in PBS. Data displayed as mean \pm SD; n=3.

Figure 6. Mucins identification by Alcian-blue PAS staining. Left panel: representative images of Caco-2 cells x400 magnification. Right panel: detail of left panel (x1000 magnification). Scale bar: 100 μ m.

Figure 7. Caco-2 cell viability evaluated by MTS assay after exposure for 2 h (a) and 24 h (b) to HSA NPs and CS-HSA NPs. Data are expressed as percentage of control (untreated group). Values represent the mean \pm SEM of at least three experiments performed in triplicate.

Figure 8. Permeation studies across Caco-2 cells. Data displayed as mean \pm SD; n=3. ** $p < 0.01$ vs HSA NPs. (ANOVA + Tukey's test).

Figure 9. Effect of different inhibitors on Caco-2 cell internalization pathways of HSA NPs and CS-HSA NPs. Data displayed as mean \pm SD; n=3. ** $p < 0.01$ vs. 37°C; #, @, °° $p < 0.05$ vs. CS-HSA NPs. (ANOVA + Tukey's test).

Figure 10. hCMEC/D3 cell viability evaluated by MTT assay (right panel) and cytotoxicity by LDH assay (left panel) when exposed for 2 h (a), and 24 h (b) to HSA NPs and CS-HSA NPs. Data are expressed as percentage of control (EBM-2 medium) and Triton-X which represent, respectively, the maximum cell viability and cell cytotoxicity. Values represent the mean \pm SEM of at least three experiments performed in triplicate. ** $p < 0.01$ vs. EBM-2 alone.


Figure 11. Permeation studies across hCMEC/D3 cells. Data displayed as mean \pm SD; n=3. * $p < 0.05$ vs HSA NPs. (ANOVA + Tukey's test).


Figure 12. Effect of different inhibitors on hCMEC/D3 cell internalization pathways of HSA NPs and CS-HSA NPs. Data displayed as mean \pm SD; n=3. ** $p < 0.01$ vs. 37°C; * $p < 0.05$ vs. 37°C. (ANOVA + Tukey's test).



Figure 13. Effect of HSA NPs and CS-HSA NPs on the gap junctions in hCMEC/D3 cells. Data displayed as mean \pm SD; n=3. * $p < 0.05$ vs. CRL. (ANOVA + Tukey's test).



Figure 14. (a) Results of the RT-PCR analyses on RNA extracted from Caco-2 and hCMEC/D3 cells exposed to HSA NPs and CS-HSA NPs, for 2 hours. Data are means \pm SE; n=3. ** $p < 0.01$ and *** $p < 0.0001$ vs control (b) Representative analysis of TJP1 expression in hCMEC/D3 and CaCo-2 cells. PCR products were separated on 1.8% agarose gel containing Safeview.





Figure 15. *Ex-vivo* permeation studies of SulfB solution, SulfB-HSA NPs and SulfB-CS-HSA NPs conjugates through rabbit nasal mucosa. Data displayed as mean \pm SD; n=3. ** $p < 0.01$ vs. SulfB solution; * $p < 0.05$ vs. SulfB solution. (ANOVA + Tukey's test).




















(a)



(b)

